

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

LC-2/ad

RRID:CVCL_1373

Type: Cell Line

Proper Citation

RRID:CVCL_1373

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1373

Proper Citation: RRID:CVCL_1373

Description: Cell line LC-2/ad is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung adenocarcinoma

Defining Citation: [PMID:8291444](#), [PMID:8348978](#), [PMID:16105816](#), [PMID:20164919](#), [PMID:22313637](#), [PMID:23154560](#), [PMID:23578175](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:35839778](#), [PMID:38639832](#)

Comments: Caution: Indicated to have a EGFR p.Leu858Arg (c.2573T>G) mutation according to PubMed=16105816) but this is in contradiction of results of exome sequencing in Cosmic-CLP and DepMap., Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LC-2/ad

Synonyms: LC-2-Ad, LC-2-ad, LC-2 ad, LC2/Ad, LC2/AD, LC2AD

Cross References: BTO:BTO_0006466, CLO:CLO_0037020, CLO:CLO_0050073, EFO:EFO_0003140, ArrayExpress:E-MTAB-3610, BioSample:SAMN03472314, cancercellines:CVCL_1373, Cell_Model_Passport:SIDM00297, ChEMBL-Cells:ChEMBL3308545, ChEMBL-Targets:ChEMBL2366260, Cosmic:907786, Cosmic:946052, Cosmic:1154602, Cosmic:1571726, Cosmic:1656903, Cosmic:1995480,

Cosmic-CLP:907786, DepMap:ACH-002157, ECACC:94072247, EGA:EGAS00001000978, GDSC:907786, GEO:GSM1670043, IARC_TP53:21470, LINCS_LDP:LCL-1667, Pharmacodb:LC2ad_831_2019, PRIDE:PXD030304, PubChem_Cell_line:CVCL_1373, RCB:RCB0440, Wikidata:Q54902124

ID: CVCL_1373

Record Creation Time: 20220427T220719+0000

Record Last Update: 20260905T181012+0000

Ratings and Alerts

No rating or validation information has been found for LC-2/ad.

No alerts have been found for LC-2/ad.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Son J, et al. (2026) Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cells. *Molecular oncology*, 20(4), 1041.

Horie M, et al. (2024) Exosomes secreted by ST3GAL5high cancer cells promote peritoneal dissemination by establishing a premetastatic microenvironment. *Molecular oncology*, 18(1), 21.

Wei X, et al. (2024) MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer. *Cancer letters*, 604, 217220.

Arbajian E, et al. (2020) Methylation Patterns and Chromatin Accessibility in Neuroendocrine Lung Cancer. *Cancers*, 12(8).

Gudernova I, et al. (2017) Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480. *Oncotarget*, 8(65), 109319.